2. Signaling Pathways
  3. Anti-infection
  4. Bacterial

Bacterial

Bacterial

Related Products

PDF 14.26 MB

Anything that destroys bacteria or suppresses their growth or their ability to reproduce. Heat, chemicals such as chlorine, and antibiotic drugs all have antibacterial properties. Many antibacterial products for cleaning and handwashing are sold today. Such products do not reduce the risk for symptoms of viral infectious diseases in otherwise healthy persons. This does not preclude the potential contribution of antibacterial products to reducing symptoms of bacterial diseases in the home.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-Y0403
    3-Chlorobenzoic acid
    		99.74%
    3-Chlorobenzoic acid (m-Chlorobenzoic acid) is the only carbon source for the bacterium.
    3-Chlorobenzoic acid
  • HY-N0216R
    Benzoic acid (Standard)
    		Inhibitor
    Benzoic acid (Standard) is the analytical standard of Benzoic acid. This product is intended for research and analytical applications. Benzoic acid is an aromatic alcohol existing naturally in many plants and is a common additive to food, drinks, cosmetics and other products. It acts as preservatives through inhibiting both bacteria and fungi.
    Benzoic acid (Standard)
  • HY-W094710
    Sodium diacetate
    		Inhibitor 99.86%
    Sodium diacetate (Sodium hydrogen diacetate) is a multifunctional biochemical reagent with antibacterial (bacteria) and antifungal (fungi) activities. Sodium diacetate exerts its antimicrobial effect mainly by effectively penetrating the cell walls of microorganisms and interfering with enzyme interactions. Sodium diacetate inhibits the growth and survival of fungi such as Botrytis cinerea, as well as bacteria such as Listeria and Escherichia coli. Sodium diacetate inhibits the growth of endothelial cells. Sodium diacetate can be used in the synthesis of food preservatives, flavoring agents and pH control additives.
    Sodium diacetate
  • HY-124452
    Nocardamine
    		Inhibitor 99.06%
    Nocardamine (Deferrioxamine E)is an iron carrier/Iron chelator with antimicrobial activity.
    Nocardamine
  • HY-160519
    Targocil-II
    		Inhibitor 98.78%
    Targocil-II (Compound 2) is an ABC transporter inhibitor with a IC50 value of 137 nM. Targocil-II prevents ATP hydrolysis by binding to allosteric sites of the TM domain. Targocil-II has (antibacterial) activity.
    Targocil-II
  • HY-17422A
    Acyclovir sodium
    		Inhibitor 99.82%
    Acyclovir (Aciclovir) sodium is a potent, orally active antiviral agent. Acyclovir sodium has antiherpetic activity with IC50 values of 0.85 μM and 0.86 μM for HSV-1 and HSV-2, respectively. Acyclovir sodium induces cell cycle perturbation and apoptosis. Acyclovir sodium prevents bacterial infections during induction therapy for acute leukaemia.
    Acyclovir sodium
  • HY-18061
    Ochromycinone
    		Inhibitor 99.61%
    Ochromycinone ((Rac)-STA-21) is a natural antibiotic and a STAT3 inhibitor. Ochromycinone can inhibits STAT3 DNA binding activity, STAT3 dimerization. Ochromycinone has anticancer and antimicrobial activity.
    Ochromycinone
  • HY-B0734A
    Cefotiam hydrochloride
    		Inhibitor 98.00%
    Cefotiam (SCE-963) hydrochloride is a parenteral cephalosporin antibiotic. Cefotiam hydrochloride has broad-spectrum activity against Gram-positive and Gram-negative bacteria.
    Cefotiam hydrochloride
  • HY-106574A
    Ceftobiprole medocaril sodium
    		Inhibitor
    Ceftobiprole medocaril (BAL5788) sodium is the parenteral proagent of Ceftobiprole (HY-112579). Ceftobiprole is a parenteral pyrrolidinone cephalosporin. Ceftobiprole is a broad-spectrum cephalosporin with high levels of in vitro activity against methicillin- (MRSA) and vancomycin-resistant staphylococci (VRSA) and penicillin-resistant streptococci. Ceftobiprole also inhibits gram-positive and gram-negative pathogens.
    Ceftobiprole medocaril sodium
  • HY-139398
    TBI-223
    		Inhibitor 99.73%
    TBI-223 is an orally active oxazolidinone antibiotic and an antimicrobial. TBI-223 shows activity against Mycobacterium tuberculosis (Mtb). TBI-223 exhibits an IC50 of 68 μg/mL for inhibiting mitochondrial protein synthesis (MPS) in HepG2 cells. TBI-223 is effective in three mouse models (bloodstream infection, skin infection, and bone infection) of methicillin-resistant staphylococcus aureus infection. TBI-223 can be used for the study of tuberculosis.
    TBI-223
  • HY-14655S
    Sulfasalazine-d4
    		Inhibitor 99.28%
    Sulfasalazine-d4 is the deuterium labeled Sulfasalazine. Sulfasalazine (NSC 667219) is an anti-rheumatic agent for the research of rheumatoid arthritis and ulcerative colitis. Sulfasalazine can suppress NF-κB activity. Sulfasalazine is a type 1 ferroptosis inducer.
    Sulfasalazine-d<sub>4</sub>
  • HY-119824
    Trofosfamide
    		Inhibitor 99.66%
    Trofosfamide is an orally bioavailable oxazaphosphorine derivative with antineoplastic activity.
    Trofosfamide
  • HY-P1630
    Buforin II
    		Inhibitor
    Buforin II, derived from buforin I, a protein isolated from the stomach of the Asian toad Bufo bufo gargarizans, is a potent antimicrobial peptide. Buforin II has antimicrobial activity against a broad spectrum of Gram-positive and Gram-negative bacteria.
    Buforin II
  • HY-W013105
    Sodium glycocholate hydrate, 98%
    		Inhibitor 99.91%
    Sodium glycocholate hydrate, 98% is a bile acid derivative. Sodium glycocholate hydrate, 98% downregulates MDR1, Bcl-2, MRP1, MRP2 and FXR, upregulates Bax, p53, caspase-9, caspase-3, TGR5 and S1PR2. Sodium glycocholate hydrate, 98% inhibits multidrug resistance and efflux pumps, induces mitochondrial apoptosis, and enhances chemosensitivity. Sodium glycocholate hydrate, 98% modulates related bile acid receptor signaling. Sodium glycocholate hydrate, 98% suppresses growth and conjugation of Enterobacteriaceae and increases their antibiotic susceptibility. Sodium glycocholate hydrate, 98% can be used for the research of colon adenocarcinoma and cholangiocarcinoma (CCA).
    Sodium glycocholate hydrate, 98%
  • HY-14743B
    Golotimod hydrochloride
    		Inhibitor 99.79%
    Golotimod hydrochloride (SCV 07 hydrochloride), an immunomodulating peptide with antimicrobial activity, significantly increases the efficacy of antituberculosis therapy, stimulates thymic and splenic cell proliferation, and improves macrophage function. Golotimod hydrochloride (SCV 07 hydrochloride) inhibits STAT3 signaling and modulates the duration and severity of oral mucositis in animal models that received radiation or a combination of radiation and Cisplatin. Golotimod hydrochloride (SCV 07 hydrochloride) is also a potential therapeutic for recurrent genital herpes simplex virus type 2 (HSV-2).
    Golotimod hydrochloride
  • HY-B1282
    Sulfaquinoxaline
    		Inhibitor 99.46%
    Sulfaquinoxaline is an antimicrobial for veterinary use, with activity against a broad spectrum of Gram-negative and Gram-positive bacteria. Sulfaquinoxaline is used to prevent coccidiosis and bacterial infections.
    Sulfaquinoxaline
  • HY-P10724
    fMIFL
    		99.79%
    fMIFL is a formyl tetrapeptide derived from Staphylococcus aureus, and also an agonist of mouse formyl peptide receptor 1 (mFPR1). It exhibits nanomolar activity against mFPR1 and micromolar activity against mFPR2. fMIFL is applicable to studies related to bacterial infections.
    fMIFL
  • HY-P2148
    P-113
    		Inhibitor 99.09%
    P-113 is an antimicrobial peptide (AMP) derived from the human salivary protein histatin 5. P-113 is active against clinically important microorganisms such as Pseudomonas spp., Staphylococcus spp., and C. albicans.
    P-113
  • HY-101412
    2-(Methylamino)-1H-purin-6(7H)-one
    		98.0%
    2-(Methylamino)-1H-purin-6(7H)-one (N2-Methylguanine) is a modified nucleoside. 2-(Methylamino)-1H-purin-6(7H)-one is an endogenous methylated nucleoside found in human fluids.
    2-(Methylamino)-1H-purin-6(7H)-one
  • HY-103249
    Reutericyclin
    		Inhibitor 98.11%
    Reutericyclin (Reutericycline) is an orally active antibacterial and anti-obesity agent that selectively inhibits Gram-positive bacteria. By selectively dissipating transmembrane potential, Reutericyclin exerts non-lytic bactericidal or bacteriostatic activity against pathogens such as Clostridium difficile and Staphylococcus aureus, and rapidly kills vegetative cells and spores of Clostridium difficile. Reutericyclin possesses favorable properties including resistance to enzymatic hydrolysis, iron-chelating function, and poor absorption by colonic epithelium. Reutericyclin not only eradicates staphylococcal biofilms and inhibits drug-resistant strains, but also counteracts Risperidone (HY-11018)-induced weight gain by inducing changes in gut microbiota composition and restoring energy utilization efficiency. Reutericyclin can be used in research related to Clostridium difficile infection, Risperidone-induced weight gain, and staphylococcal superficial skin infections.
    Reutericyclin
Cat. No. Product Name / Synonyms Application Reactivity